scholarly journals Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma

2019 ◽  
Vol 110 (2) ◽  
pp. 726-733 ◽  
Author(s):  
Kazue Yoneda ◽  
Taiji Kuwata ◽  
Yasuhiro Chikaishi ◽  
Masataka Mori ◽  
Masatoshi Kanayama ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Malignant Pleural Mesothelioma ◽  
Microfluidic System ◽  
Pleural Mesothelioma

Abstract 5103: Development of detecting systems for circulating tumor cells in malignant pleural mesothelioma patients.

2013 ◽  
Author(s):  
Chikaishi Yasuhiro ◽  
Tomoko So ◽  
Soichi Oka ◽  
Masaru Takenaka ◽  
Makoto Nakagawa ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma

2012 ◽  
Vol 6 (3) ◽  
pp. 171-173 ◽  
Author(s):  
Giulia Pinton ◽  
Arcangela Gabriella Manente ◽  
Laura Moro ◽  
Luciano Mutti
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Diagnostic Test ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

scholarly journals Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 888
Author(s):  
Taiji Kuwata ◽  
Kazue Yoneda ◽  
Masataka Mori ◽  
Masatoshi Kanayama ◽  
Koji Kuroda ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Malignant Pleural Mesothelioma ◽  
Circulating Tumor Cell ◽  
Microfluidic System ◽  
Clinical Implications ◽  
Pleural Mesothelioma ◽  
Rare Tumor ◽  
Podoplanin Expression ◽  
Higher Sensitivity

Circulating tumor cell (CTC) is a potentially useful surrogate of micro-metastasis, but detection of rare tumor cells contaminated in a vast majority of normal hematologic cells remains technical challenges. To achieve effective detection of a variety of CTCs, we have developed a novel microfluidic system (CTC-chip) in which any antibody to capture CTCs is easily conjugated. In previous studies, we employed an antibody (clone E-1) against podoplanin that was strongly expressed on mesothelioma cells. The CTC-chip coated by the E-1 antibody (E1-chip) provided a modest sensitivity in detection of CTCs in malignant pleural mesothelioma (MPM). Here, to achieve a higher sensitivity, we employed a novel anti-podoplanin antibody (clone NZ-1.2). In an experimental model, MPM cells with high podoplanin expression were effectively captured with the CTC-chip coated by the NZ-1.2 antibody (NZ1.2-chip). Next, we evaluated CTCs in the peripheral blood sampled from 22 MPM patients using the NZ1.2-chip and the E1-chip. One or more CTCs were detected in 15 patients (68.2%) with the NZ1.2-chip, whereas only in 10 patients (45.5%) with the E1-chip. Of noted, in most (92.3%, 12/13) patients with epithelioid MPM subtype, CTCs were positive with the NZ1.2-chip. The CTC-count detected with the NZ1.2-chip was significantly higher than that with the E1-chip (p = 0.034). The clinical implications of CTCs detected with the NZ1.2-chip will be examined in a future study.

Clinical application of a novel CTC-chip to detect circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e24086-e24086
Author(s):  
Kazue Yoneda ◽  
Taiji Kuwata ◽  
Yasuhiro Chikaishi ◽  
Yoshinobu Ichiki ◽  
Takashi Ohnaga ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Application ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM)

2013 ◽  
Vol 21 (S4) ◽  
pp. 472-480 ◽  
Author(s):  
Kazue Yoneda ◽  
Fumihiro Tanaka ◽  
Nobuyuki Kondo ◽  
Masaki Hashimoto ◽  
Teruhisa Takuwa ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

scholarly journals Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay

2018 ◽  
Vol 115 (40) ◽  
pp. 9986-9991 ◽  
Author(s):  
Manjima Dhar ◽  
Jeffrey Nam Lam ◽  
Tonya Walser ◽  
Steven M. Dubinett ◽  
Matthew B. Rettig ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Activity Ratio ◽  
Proteolytic Enzymes ◽  
Microfluidic System ◽  
Matrix Metalloprotease ◽  
Rare Cancer ◽  
Companion Diagnostics ◽  
Functional Profiling ◽  
Vortex Capture

Tumor cells are hypothesized to use proteolytic enzymes to facilitate invasion. Whether circulating tumor cells (CTCs) secrete these enzymes to aid metastasis is unknown. A quantitative and high-throughput approach to assay CTC secretion is needed to address this question. We developed an integrated microfluidic system that concentrates rare cancer cells >100,000-fold from 1 mL of whole blood into ∼50,000 2-nL drops composed of assay reagents within 15 min. The system isolates CTCs by size, exchanges fluid around CTCs to remove contaminants, introduces a matrix metalloprotease (MMP) substrate, and encapsulates CTCs into microdroplets. We found CTCs from prostate cancer patients possessed above baseline levels of MMP activity (1.7- to 200-fold). Activity of CTCs was generally higher than leukocytes from the same patient (average CTC/leukocyte MMP activity ratio, 2.6 ± 1.5). Higher MMP activity of CTCs suggests active proteolytic processes that may facilitate invasion or immune evasion and be relevant phenotypic biomarkers enabling companion diagnostics for anti-MMP therapies.

Sign in / Sign up

Export Citation Format

Share Document